NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies - RRMM Myeloma
NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in...
Dec 12, 2019
17th International Myeloma Workshop: September 12-15, 2019 Boston, MA
17th International Myeloma Workshop September 12-15, 2019 Boston, MA http://www.imw2019boston.org/ https://www.myelomasociety.org/publica...
Dec 12, 2019
Dana-Farber's 2019 Multiple Myeloma Patient Symposium - | Current & Future Treatment
Watch on YouTube 2019 Multiple Myeloma Symposium | Current & Future Treatment Dana-Farber Cancer Institute Jan 23, 2020 Learn more:...
Dec 12, 2019
Nature Video: Decoding cancer immunology: Hunting hidden tumours
Nature Video: Decoding cancer immunology: Hunting hidden tumours
Dec 12, 2019
NCT04150965: Phase 1/2: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Multiple Myeloma Research Consortium MMRC-089: A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3...
Dec 12, 2019
Myeloma Canada: Patient Handbook - High-dose Therapy and Autologous Stem Cell Transplantation
Myeloma Canada: Patient Handbook - High-dose Therapy and Autologous Stem Cell Transplantation https://myelome.ca/documents/HighDoseTherap...
Dec 12, 2019